Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    ARS Pharmaceuticals Inc.

    NASDAQ: SPRY · Real-Time Price · USD
    15.13
    -0.26 (-1.69%)
    At close: Jun 16, 2025, 3:59 PM
    15.24
    0.73%
    After-hours: Jun 16, 2025, 05:56 PM EDT
    -1.69%
    Bid 14.8
    Market Cap 1.49B
    Revenue (ttm) 97.12M
    Net Income (ttm) -15.65M
    EPS (ttm) -0.16
    PE Ratio (ttm) -94.56
    Forward PE -20.29
    Analyst Buy
    Ask 15.8
    Volume 753,921
    Avg. Volume (20D) 1,674,082
    Open 15.62
    Previous Close 15.39
    Day's Range 14.86 - 15.68
    52-Week Range 7.55 - 18.51
    Beta 0.87

    About SPRY

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol SPRY
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for SPRY stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    1 month ago
    +11.48%
    ARS Pharmaceuticals shares are trading higher on p... Unlock content with Pro Subscription
    2 months ago
    +22.83%
    ARS Pharmaceuticals shares are trading higher. The company reported Q4 financial results.
    news image

    1 month ago · seekingalpha.com

    ARS Pharmaceuticals, Inc. (SPRY) Q1 2025 Earnings Call Transcript

    ARS Pharmaceuticals, Inc. (NASDAQ:SPRY ) Q1 2025 Earnings Conference Call May 14, 2025 8:30 AM ET Company Participants Justin Chakma - CBO Richard Lowenthal - Co-Founder, President and CEO Eric Karas ...

    news image

    1 month ago · zacks.com

    ARS Pharmaceuticals, Inc. (SPRY) Reports Q1 Loss, Lags Revenue Estimates

    ARS Pharmaceuticals, Inc. (SPRY) came out with a quarterly loss of $0.35 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.11 per share a year ago.

    news image

    1 month ago · seekingalpha.com

    ARS Pharmaceuticals Has A Blockbuster Candidate

    ARS Pharmaceuticals has a recently launched needle-free epinephrine product for allergic reactions, neffy, and strong cash reserves. The company targets a ~$3B+ U.S. market, geographic expansion and i...

    news image

    2 months ago · seekingalpha.com

    ARS Pharmaceuticals: Surging On Solid Earnings - But Real Challenges Await

    ARS Pharmaceuticals, Inc.'s stock surged 25% today after strong Q4 and full-year 2024 earnings, driven by the needle-free epinephrine treatment, neffy, which has promising market potential. Neffy's co...

    news image

    2 months ago · seekingalpha.com

    ARS Pharmaceuticals, Inc. (SPRY) Q4 2024 Earnings Conference Call Transcript

    ARS Pharmaceuticals, Inc. (NASDAQ:SPRY ) Q4 2024 Earnings Conference Call March 20, 2025 8:30 AM ET Company Participants Justin Chakma - Chief Business Officer Richard Lowenthal - Co-Founder, Presiden...

    news image

    2 months ago · investors.com

    ARS Pharma Retakes Its 50-Day Line In Bullish Post-Earnings Move. Here's Why.

    Shares of ARS Pharmaceuticals bounded higher Thursday after the company reported an unexpected fourth-quarter metrics. The post ARS Pharma Retakes Its 50-Day Line In Bullish Post-Earnings Move.

    news image

    2 months ago · zacks.com

    ARS Pharmaceuticals, Inc. (SPRY) Q4 Earnings and Revenues Beat Estimates

    ARS Pharmaceuticals, Inc. (SPRY) came out with quarterly earnings of $0.52 per share, beating the Zacks Consensus Estimate of a loss of $0.04 per share. This compares to loss of $0.07 per share a year...

    Add to Watchlist